Abbott Laboratories
ABT
$105.90
-$0.02-0.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 11.00% | 4.44% | 4.32% | 27.59% | -28.01% |
| Total Depreciation and Amortization | -1.33% | 3.00% | -0.74% | -0.12% | -0.98% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 105.13% | -11.36% | -53.02% | -14.85% | 168.29% |
| Change in Net Operating Assets | 178.20% | 54.71% | 12.52% | -908.97% | -61.67% |
| Cash from Operations | 61.85% | 56.03% | 5.25% | -50.86% | -16.33% |
| Capital Expenditure | -34.82% | -10.45% | -33.42% | 37.70% | -30.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | 93.83% | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -200.00% | -128.75% | 197.56% | -272.73% | -29.41% |
| Cash from Investing | -29.97% | 47.73% | -162.55% | 26.90% | -30.58% |
| Total Debt Issued | -- | -100.00% | -- | -- | -60.00% |
| Total Debt Repaid | 36.19% | -13,790.91% | 126.19% | -- | 100.00% |
| Issuance of Common Stock | -39.29% | 273.33% | -75.81% | 51.22% | -28.07% |
| Repurchase of Common Stock | -12,850.00% | 99.53% | 21.11% | 21.17% | 14.16% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00% | 0.22% | 0.00% | -8.14% | 0.36% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.31% | -81.54% | 8.58% | 3.23% | 5.57% |
| Foreign Exchange rate Adjustments | 186.21% | -7.41% | -437.50% | -84.31% | 153.13% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 116.61% | 15.08% | -83.91% | -350.35% | -56.16% |
